Evidence map›Paper›PMID 33893050›Full record

ArticleCytotherapy2021

Multiply restimulated human thymic regulatory T cells express distinct signature regulatory T-cell transcription factors without evidence of exhaustion.

Keli L Hippen, Scott N Furlan, Rahul Roychoudhuri, Ena Wang, Yigang Zhang, Mark J Osborn, Sarah C Merkel, Sophia Hani, Margaret L MacMillan, Frank Cichocki and 5 more

Open access · greenAbstract read
In one paragraph

Article in Cytotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Tonic-signaling chimeric antigen receptors drive human regulatory T cell exhaustion.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 2 countries.

Keli L HippenDepartment of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota Cancer Center, Minneapolis, Minnesota, USA. Electronic address: hippe002@umn.edu.
Scott N FurlanBen Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, Washington, USA; Department of Pediatrics, University of Washington, Seattle, Washington, USA.
Rahul RoychoudhuriLaboratory of Lymphocyte Signaling and Development, Babraham Institute, Cambridge, UK.
Ena WangTranslational Oncology, Allogene Therapeutics, San Francisco, California, USA.
Yigang ZhangDepartment of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota Cancer Center, Minneapolis, Minnesota, USA.
Mark J OsbornDepartment of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota Cancer Center, Minneapolis, Minnesota, USA.
Sarah C MerkelDepartment of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota Cancer Center, Minneapolis, Minnesota, USA.
Sophia HaniDepartment of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota Cancer Center, Minneapolis, Minnesota, USA.
Margaret L MacMillanDepartment of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota Cancer Center, Minneapolis, Minnesota, USA.
Frank CichockiDepartment of Medicine, Division of Hematology/Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota, USA.
Jeffrey S MillerDepartment of Medicine, Division of Hematology/Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota, USA.
John E WagnerDepartment of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota Cancer Center, Minneapolis, Minnesota, USA.
Nicholas P RestifoCancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Leslie S KeanDivision of Pediatric Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Bruce R BlazarDepartment of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota Cancer Center, Minneapolis, Minnesota, USA. Electronic address: blaza001@umn.edu.
University of Minnesota Medical Center · USMasonic Cancer CenterUniversity of Minnesota · USAllogene Therapeutics (United States) · USBabraham Institute · GBDana-Farber Cancer Institute · USNational Institutes of Health · USUniversity of Washington · US

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Douglas Yee · 1998 to 2026
$100.4M
Transplant Tolerance in Non-Human PrimatesU19AI051731 · NIAID · UNIVERSITY OF WESTERN ONTARIO · PI LARSEN, CHRISTIAN P. · 2002 to 2022
$54.1M
Trial Design and Biostatistical Support CoreP01CA065493 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Mark J Osborn · 1995 to 2026
$48.2M
Transgenic/KnockoutP01AI056299 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI FREEMAN, GORDON JAMES · 2003 to 2023
$42.5M
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR000114 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R · 2012 to 2015
$35.0M
Novel Biologic Therapies for GVHDR01HL095791 · NHLBI · SEATTLE CHILDREN'S HOSPITAL · PI KEAN, LESLIE S · 2010 to 2025
$13.3M
Enhancing Treg Therapeutic Efficacy in GVHDR01HL118979 · NHLBI · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, HIPPEN, KELI L · 2014 to 2025
$6.7M
In Vivo Prevention of Murine GVHDR37AI034495 · NIAID · UNIVERSITY OF MINNESOTA · PI Bruce R Blazar · 2017 to 2026
$5.4M
Nongenotoxic conditioning for gene therapy and allogeneic transplantation in Fanconi anemiaR01HL147324 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Bruce R Blazar, HANS-PETER KIEM · 2020 to 2026
$4.1M
Inducible Regulatory T Cells for the Prevention and Treatment of Acute GVHDR01HL114512 · NHLBI · UNIVERSITY OF MINNESOTA · PI MACMILLAN, MARGARET L · 2012 to 2016
$3.0M
INVASIVE GLIOMA CELLSF32CA067493 · NCI · WASHINGTON UNIVERSITY · PI CHICOINE, MICHAEL R · 1995 to 1996
–
NCATS NIH HHS UL1 TR000114NCI NIH HHS F32 CA067493NCI NIH HHS P01 CA065493NCI NIH HHS P30 CA077598NHLBI NIH HHS N01 HB037164NHLBI NIH HHS R01 HL095791NHLBI NIH HHS R01 HL114512NHLBI NIH HHS R01 HL118979NHLBI NIH HHS R01 HL147324NIAID NIH HHS P01 AI056299NIAID NIH HHS R37 AI034495NIAID NIH HHS U19 AI051731
6 · The paper itself

Abstract

BACKGROUND

aimsAdoptive transfer of suppressive CD4+CD25+ thymic regulatory T cells (tTregs) can control auto- and alloimmune responses but typically requires in vitro expansion to reach the target cell number for efficacy. Although the adoptive transfer of expanded tTregs purified from umbilical cord blood ameliorates graft-versus-host disease in patients receiving hematopoietic stem cell transplantation for lymphohematopoietic malignancy, individual Treg products of 100 × 10

resultsPreviously, the authors reported a repetitive restimulation expansion protocol that maintains Treg phenotype (CD4+25++127-Foxp3+), potentially providing hundreds to thousands of patient infusions. However, repetitive stimulation of effector T cells induces a well-defined program of exhaustion that leads to reduced T-cell survival and function. Unexpectedly, the authors found that multiply stimulated human tTregs do not develop an exhaustion signature and instead maintain their Treg gene expression pattern. The authors also found that tTregs expanded with one or two rounds of stimulation and tTregs expanded with three or five rounds of stimulation preferentially express distinct subsets of a group of five transcription factors that lock in Treg Foxp3expression, Treg stability and suppressor function. Multiply restimulated Tregs also had increased transcripts characteristic of T follicular regulatory cells, a Treg subset. DISCUSSION: These data demonstrate that repetitively expanded human tTregs have a Treg-locking transcription factor with stable FoxP3 and without the classical T-cell exhaustion gene expression profile-desirable properties that support the possibility of off-the-shelf Treg therapeutics.

Indexed as

Graft vs Host DiseaseT-Lymphocytes, RegulatoryAdoptive TransferFetal BloodForkhead Transcription FactorsHumansForkhead Transcription Factorscell therapycGMP productiongraft-versus-host diseaseregulatory T cellTreg

Identifiers

PMID33893050
PMCPMC9275118
OpenAlexW3152966026

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.